Loblaw Companies Limited provided sales guidance for the second half and full year of 2022. Loblaw anticipates that in the first half of 2022 sales will benefit from the continued impact of the pandemic and elevated industry-wide inflation.

As societies and economies reopen and the Company starts to lap elevated 2021 inflationary prices and COVID-19 related pharmacy services, year on year revenue growth will be more challenged. The company expects earnings per common Share growth in the low double digits, with higher growth in the first half of the year.